The LINFU® U.S. Registry for the in the General Population Without Risk Factors

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

September 15, 2034

Study Completion Date

December 15, 2034

Conditions
Pancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Dysplasia
Interventions
DIAGNOSTIC_TEST

LINFU®

Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes using a GE LOGIQ10 or other FDA approved, FDA cleared or FDA exempt ultrasound insonation. A contrast agent will be administered IV during the ultrasound insonation and the patient will also receive a dose of secretin. The pancreatic juice will then be collected for a total of 15 minutes.

All Listed Sponsors
lead

Adenocyte, LLC

INDUSTRY

NCT06276803 - The LINFU® U.S. Registry for the in the General Population Without Risk Factors | Biotech Hunter | Biotech Hunter